TEST:

FoundationOne®Monitor

FoundationOne Monitor provides unique access to Foundation Medicine’s ctDNA tumor fraction biomarker that incorporates information to improve sensitivity and maintain high specificity to monitor ctDNA levels. The test also has capabilities for assessing resistance to therapy across more than 300 genes. FoundationOne Monitor expands Foundation Medicine’s monitoring portfolio, providing therapy developers with an additional option for use when studying treatment response, particularly when there is no tumor tissue available for testing.